(2002; 166 pages)
Moderators: Dr Harald G. Schweim, Germany, and Ms
Yupin Lawanprasert, Thailand
Many drug regulatory authorities have little knowledge about homoeopathic principles, and are unsure how to evaluate the safety of these highly diluted products, how to carry out meaningful stability testing, or how to assess new homoeopathic products. Recent reports of adverse effects of homoeopathic treatment have raised concerns about how to ensure safety. The objectives of this session were to allow DRAs to exchange their knowledge and experience of regulation of homoeopathic medicines, discuss how to ensure quality control of the highly diluted products, and consider how to educate consumers in their proper use.